Document Detail

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine.
MedLine Citation:
PMID:  11481700     Owner:  NLM     Status:  MEDLINE    
An open pilot study with the dopamine agonist alpha-dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug-free interval of 1 week, the patients were treated with daily doses of 10 to 40 mg DHEC. As compared to baseline values, treatment led to a statistically significant reduction of subjective RLS symptoms. Overall complaints at night decreased significantly by 63.9 +/- 38.1% as measured by a visual analogue scale. Detailed evaluation of sensory discomfort, motor restlessness, involuntary movements, as well as sleep quality also showed significant improvement. Side effects were mostly mild and affected mainly the gastrointestinal tract. Five patients needed domperidone for treatment of concomitant nausea. One patient stopped the study due to nausea. In conclusion, the results of this open study suggest a role for DHEC in the treatment of RLS.
F Tergau; S Wischer; C Wolf; W Paulus
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  16     ISSN:  0885-3185     ISO Abbreviation:  Mov. Disord.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-08-01     Completed Date:  2001-10-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  731-5     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Movement Disorder Society.
Department of Clinical Neurophysiology, Georg-August University Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dihydroergotoxine / adverse effects,  therapeutic use*
Dopamine Agonists / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Middle Aged
Pain Measurement
Pilot Projects
Prospective Studies
Restless Legs Syndrome / drug therapy*
Reg. No./Substance:
0/Dopamine Agonists; 11032-41-0/Dihydroergotoxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Familial paroxysmal exercise-induced dyskinesia, epilepsy, and mental retardation in a family with a...
Next Document:  Focal myopathy as a cause of anterocollis in Parkinsonism.